294 A.3d 65
Del. Ch.2023Background
- Walmart operated >5,000 retail pharmacies and, until April 2018, self-distributed prescription opioids; it entered a DEA settlement (Mar 11, 2011–Mar 11, 2015) requiring pharmacy compliance systems.
- Internal materials (as alleged) show delayed/underfunded implementation of suspicious-order monitoring and diversion-analytics; plaintiffs infer conscious prioritization of sales over compliance.
- Plaintiffs (three institutional stockholders) brought a derivative suit alleging three fiduciary-breach theories: Information‑Systems Claim (failure to implement monitoring systems), Red‑Flags Claim (ignored warning signs), and Massey Claim (conscious decision to prioritize profits over compliance).
- Plaintiffs pursued Section 220 books-and-records demands in May–Aug 2020, obtained documents, then filed the derivative complaint Sept. 27, 2021.
- Defendants moved to dismiss primarily on laches/timeliness; the court addressed accrual method, lookback date, the three categories of underlying misconduct (Pharmacy, Distributor, DEA‑Settlement), and tolling/inquiry‑notice doctrines.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Proper accrual method for an Information‑Systems Claim | Use continuing‑wrong or otherwise treat claim as ongoing because failure to implement systems is a persistent wrong | Use discrete‑act or other accrual rules to bar stale claims | Court adopts the separate‑accrual approach for Information‑Systems Claims (aligning with Red‑Flags and Massey claims) |
| Lookback date under separate‑accrual approach | Lookback should be tied to diligent pursuit of books/records (Section 220 demands) | Lookback should be filing date of complaint or later dates | Court uses May 4, 2020 (first Section 220 demand) as lookback date because plaintiffs diligently pursued records |
| Timeliness of Pharmacy and Distributor claims | Ongoing misconduct continued into actionable period (after May 4, 2017) so claims are timely | Claims are untimely under laches/statute of limitations | Pharmacy claims timely (ongoing dispensing issues; post‑period injunction and settlement support continuity); Distributor claims timely (management exited distribution Nov 2017–Apr 2018, overlapping actionable period) |
| Timeliness of DEA‑Settlement claims; equitable tolling & inquiry notice | DEA‑Settlement misconduct occurred 2011–2015 but equitable tolling applies because defendants concealed the settlement and fiduciaries reassured stockholders; tolling runs until inquiry notice (arguably March 2020 ProPublica disclosure) | Opioid MDL filings and public litigation put stockholders on inquiry notice earlier (2016–2017), defeating tolling | Court rejects dismissal on face of complaint: equitable tolling is available until point of inquiry notice; the record does not show as a matter of law that Opioid MDL filings gave inquiry notice of the undisclosed DEA settlement, so DEA‑Settlement claims may be timely (tolling likely until March 2020) |
Key Cases Cited
- Lebanon Cnty. Emps.’ Ret. Fund v. Collis, 287 A.3d 1160 (Del. Ch. 2022) (adopts separate‑accrual approach for Red‑Flags Claims and frames accrual analysis)
- Stone v. Ritter, 911 A.2d 362 (Del. 2006) (oversight liability requires bad faith; Caremark framework)
- In re Caremark Int’l Inc. Deriv. Litig., 698 A.2d 959 (Del. Ch. 1996) (landmark statement on board oversight and information‑system duties)
- Guttman v. Huang, 823 A.2d 492 (Del. Ch. 2003) (director oversight liability requires bad faith)
- Marchand v. Barnhill, 212 A.3d 805 (Del. 2019) (oversight duty as good‑faith effort to be informed; exculpation irrelevant to bad‑faith oversight)
- In re McDonald’s Corp. S’holder Deriv. Litig., 289 A.3d 348 (Del. Ch. 2023) (discusses Information‑Systems and Red‑Flags claim contours)
- In re Am. Int’l Grp., Inc. Consol. Deriv. Litig., 965 A.2d 763 (Del. Ch. 2009) (equitable tolling doctrine where fiduciaries concealed misconduct)
- In re Tyson Foods, Inc. Consol. S’holder Litig., 919 A.2d 563 (Del. Ch. 2007) (equitable tolling while plaintiffs reasonably rely on fiduciaries’ good faith)
Decision: defendants’ laches motion denied; Pharmacy and Distributor claims are timely; DEA‑Settlement claims survive at pleading stage because equitable tolling and unresolved inquiry‑notice issues preclude dismissal.